Pure Global
NCT06364787

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

The Safety and Efficacy Assessment of Allogeneic γδ T Cells Combined With Targeted Therapy and Immunotherapy in Hepatocellular Carcinoma Patients
Beijing 302 Hospital·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
γδ T cells
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Beijing 302 Hospital
Timeline & enrollment
Phase
Phase 1
Start date
Apr 26, 2024
End date
Sep 26, 2026
Enrollment
18 participants
Primary outcome

Safety evaluation: Incidence of Adverse events (AEs),Safety evaluation: Dose limited toxicity (DLTs),Safety evaluation: Maximum-tolerated dose (MTD),Efficacy evaluation: Objective Response Rate(ORR),Efficacy evaluation: Duration of Response(DOR),Efficacy evaluation: Progress Free Survival(PFS),Efficacy evaluation: Overall Survival (OS)

Summary

The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells
 combined with targeted therapy and PD-1 monoclonal antibody in first-line treatment of
 patients with hepatocellular carcinoma.

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06364787
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06364787 through Pure Global AI's free database. This Phase 1 trial is sponsored by Beijing 302 Hospital and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.